Market research
1UC.F Cue Biopharma, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 29.83
- Dividend yield
- Not available
- Beta
- 1.58
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US22978P1066
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 29.83
- Dividend yield
- Not available
- Beta
- 1.58
About
About Cue Biopharma, Inc
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 1UC.F discussion.
5 years, 5 months ago
Cue Biopharma, Inc is currently in a long term downtrend where the price is trading 18.2% below its 200 day moving average.
From a valuation standpoint, the stock is 91.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 108.8.
Cue Biopharma, Inc's total revenue sank by 54.7% to $475K since the same quarter in the previous year.
Its net income has dropped by 24.5% to $-11M since the same quarter in the previous year.
Finally, its free cash flow fell by 10.2% to $-7M since the same quarter in the previous year.
Based on the above factors, Cue Biopharma, Inc gets an overall score of 1/5.